Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure

Basit Öğe Kaydı
dc.contributor.authorAlkis, N.
dc.contributor.authorDemirci, U.
dc.contributor.authorBenekli, M.
dc.contributor.authorYilmaz, U.
dc.contributor.authorIsikdogan, A.
dc.contributor.authorSevinc, A.
dc.contributor.authorOzdemir, N. Y.
dc.date.accessioned2024-04-24T17:37:39Z
dc.date.available2024-04-24T17:37:39Z
dc.date.issued2011
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: To retrospectively evaluate the efficacy and tolerability of mitomycin-C (MMC) in combination with fluoropyrimidines as salvage 3rd -or 4th-line therapy in metastatic colorectal cancer (MCRC) patients. Methods: All patients in this study had previously failed oxaliplatin and irinotecan-based chemotherapy. Patients were treated with MMC (6 mg/m(2) intravenously/i.v) on day 1 in combination with either oral UFT (500 mg/m(2)) and oral leucovorin (LV) (30 mg) on days 1-14 every 3 weeks (group A) or infusional 5-fluorouracil (5-FU) by deGramont regimen with i.v. LV (200 mg/m(2)) on days I and 2, every 2 weeks (group B). Results: Thirty-nine MCRC patients were analyzed. Twenty-two of them were in group A and 17 in group B. Thirty-three were evaluable for clinical efficacy The clinical benefit in the intent-to-treat (ITT) population was 30.8%. Median progression free survival (PFS) was 6 months (95% confidence interval/CI 4-8) and median overall survival (OS) 9 months (95% CI 6.5-11.5). Median PFS was 3 months (95% CI 2.4-3.6) in group A and 7 months (95% CI 5.1-8.9) in group B (p=0.009). Median OS was 7 months (95% CI 4.3-9.7) in group A and 12 months (95% CI 5.4-18.6) in group B (p=0.422). The combination of MMC and fluoropyrimidines was generally well tolerated. The most common severe toxicities were nausea and vomiting, neutropenia, hepatotoxicity and diarrhea. Conclusion: MMC in combination with fluoropyrimidines is safe and active in heavily-pretreated MCRC patients. This combination remains a viable option in these patients. However better therapies are urgently needed.en_US
dc.identifier.endpage83en_US
dc.identifier.issn1107-0625
dc.identifier.issue1en_US
dc.identifier.pmid21674854en_US
dc.identifier.scopus2-s2.0-79954507349en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage80en_US
dc.identifier.urihttps://hdl.handle.net/11468/21097
dc.identifier.volume16en_US
dc.identifier.wosWOS:000289384100011
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherZerbinis Medical Publen_US
dc.relation.ispartofJournal of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFluoropyrimidinesen_US
dc.subjectMetastatic Colorectal Canceren_US
dc.subjectMitomycin-Cen_US
dc.subjectSalvage Therapyen_US
dc.titleMitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu